TrialESMO open2026

A phase II randomized trial of gemcitabine plus cisplatin (GP) versus gemcitabine plus carboplatin (GC) as the first-line treatment of patients with metastatic triple-negative breast cancer.

C Gong et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.